The proof-of-concept study for TRV734 resumes following NIDA ‘s recruitment of patients. In addition, Trevena Inc (NASDAQ: TRVN) announces its move today, pointing to the move towards the right direction in activities centered on developing and commercializing novel medicines to support struggling patients. The company has, over the years, sought out working solutions to support patients struggling with central nervous system (CNS) disorders.
Carrie Bourdow speaks out on the recent developments
The President and Chief Executive Officer of Trevena, Inc, Carrie Bourdow, considers the Opioid use disorder a sensitive matter that must be taken with utmost seriousness before it ruins many lives. He has openly termed the matter as an issue of great public concern.
The official acknowledges the veracity of the COVID-19 outbreak but also cites Opioid use disorder as a matter that deserves attention. He calls out for co-operation towards developing working solutions to serve the struggling patient populations with effective treatment. The official is inclined towards continuing activities geared towards developing effective treatments for patients struggling with opioid addiction.
Bourdow opined, “NIDA’s resumption of their study for TRV734, which may offer an effective treatment option with improved tolerability compared to the current standard of care, underscores the unmet need for treatments for OUD.”
The robust collaboration between Trevena and NIH marks a great start towards developing longstanding partnerships focused on the exploration of several important pipeline assets.
The NIDA study of TRV734 is a great addition to Trevena’s portfolio. Considering that it is the third investigational drug product within the company’s pipeline that the NIH focused upon.
Trevena refers to the study as a double-blind positive-controlled study that will incorporate about 50 opioid-dependent patients.